Physician profile
Michael K Margolis
NPI 1235120551
$3,971.49
in general payments reported to CMS, 2019-2025
44 companies · $494 in 2025
The $494 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $705 · 2020: $156 · 2021: $291 · 2022: $798 · 2023: $611 · 2024: $917 · 2025: $494.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,022.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,022.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $682.79 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $437.74 | 2019-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Amgen INC. | $353.50 | 2019-2025 | Otezla, Repatha, Evenity |
| Depuy Synthes Sales INC. | $340.22 | 2021-2024 | Na, Va-Lcp, Fibergraft Aeridyan Matrix |
| Lilly USA, LLC | $278.07 | 2020-2024 | Mounjaro, Zepbound, Trulicity |
| Novartis Pharmaceuticals Corporation | $253.24 | 2019-2023 | |
| Astellas Pharma US INC | $197.86 | 2019-2023 | Veozah |
| Merck Sharp & Dohme LLC | $134.50 | 2020-2023 | Verquvo, Belsomra, Steglatro |
| Integra Lifesciences Corporation | $134.32 | 2023 | Integra, Primatrix, Integra Dermal Regeneration Template |
| Pfizer INC. | $115.64 | 2020-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $88.12 | 2019-2024 | Xifaxan |
| Bayer Healthcare Pharmaceuticals INC. | $69.37 | 2021-2024 | |
| Abbvie INC. | $61.76 | 2022-2025 | |
| Exact Sciences Corporation | $58.36 | 2024-2025 | Cologuard Collection Kit |
| Abiomed | $55.78 | 2024-2025 |
Show all 44 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Margolis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.